Wladimir Bocca Vieira de Rezende Pinto

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes

Antônio Edvan Camelo-Filho, André Macedo Serafim da Silva, Eduardo de Paula Estephan et al. · Frontiers in Neurology · 2020 · 105 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

One family, one gene and three phenotypes: A novel VCP (valosin-containing protein) mutation associated with myopathy with rimmed vacuoles, amyotrophic lateral sclerosis and frontotemporal dementia

Agessandro Abrahão, Osório Lopes Abath Neto, Fernando Kok et al. · Journal of the Neurological Sciences · 2016 · 46 citations

Life Sciences, Genetics, Molecular Genetics +15